319 related articles for article (PubMed ID: 29851098)
1. Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis.
Nielsen MJ; Thorburn D; Leeming DJ; Hov JR; Nygård S; Moum B; Saffioti F; Gilja OH; Boberg KM; Mazza G; Røsjø H; Pinzani M; Karlsen TH; Karsdal MA; Vesterhus M
Aliment Pharmacol Ther; 2018 Jul; 48(2):179-189. PubMed ID: 29851098
[TBL] [Abstract][Full Text] [Related]
2. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study.
de Vries EMG; Färkkilä M; Milkiewicz P; Hov JR; Eksteen B; Thorburn D; Chazouillères O; Pares A; Nygård S; Gilja OH; Wunsch E; Invernizzi P; Carbone M; Bernuzzi F; Boberg KM; Røsjø H; Rosenberg W; Beuers UH; Ponsioen CY; Karlsen TH; Vesterhus M
Liver Int; 2017 Oct; 37(10):1554-1561. PubMed ID: 28267887
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease.
Vesterhus M; Nielsen MJ; Hov JR; Saffioti F; Manon-Jensen T; Leeming DJ; Moum B; Boberg KM; Pinzani M; Karlsen TH; Karsdal MA; Thorburn D
JHEP Rep; 2021 Feb; 3(1):100178. PubMed ID: 33225252
[TBL] [Abstract][Full Text] [Related]
4. Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis.
Tornai T; Palyu E; Vitalis Z; Tornai I; Tornai D; Antal-Szalmas P; Norman GL; Shums Z; Veres G; Dezsofi A; Par G; Par A; Orosz P; Szalay F; Lakatos PL; Papp M
World J Gastroenterol; 2017 Aug; 23(29):5412-5421. PubMed ID: 28839442
[TBL] [Abstract][Full Text] [Related]
5. Serum markers of type III and IV procollagen processing predict recurrence of fibrosis in liver transplanted patients.
Nielsen MJ; Villesen IF; Gudmann NS; Leeming DJ; Krag A; Karsdal MA; Zimmermann T; Schuppan D
Sci Rep; 2019 Oct; 9(1):14857. PubMed ID: 31619707
[TBL] [Abstract][Full Text] [Related]
6. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.
Vesterhus M; Holm A; Hov JR; Nygård S; Schrumpf E; Melum E; Thorbjørnsen LW; Paulsen V; Lundin K; Dale I; Gilja OH; Zweers SJLB; Vatn M; Schaap FG; Jansen PLM; Ueland T; Røsjø H; Moum B; Ponsioen CY; Boberg KM; Färkkilä M; Karlsen TH; Lund-Johansen F
J Hepatol; 2017 Jun; 66(6):1214-1222. PubMed ID: 28161472
[TBL] [Abstract][Full Text] [Related]
7. Extracellular Matrix Fragments of the Basement Membrane and the Interstitial Matrix Are Serological Markers of Intestinal Tissue Remodeling and Disease Activity in Dextran Sulfate Sodium Colitis.
Lindholm M; Manon-Jensen T; Madsen GI; Krag A; Karsdal MA; Kjeldsen J; Mortensen JH
Dig Dis Sci; 2019 Nov; 64(11):3134-3142. PubMed ID: 31123972
[TBL] [Abstract][Full Text] [Related]
8. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis.
Vesterhus M; Hov JR; Holm A; Schrumpf E; Nygård S; Godang K; Andersen IM; Naess S; Thorburn D; Saffioti F; Vatn M; Gilja OH; Lund-Johansen F; Syversveen T; Brabrand K; Parés A; Ponsioen CY; Pinzani M; Färkkilä M; Moum B; Ueland T; Røsjø H; Rosenberg W; Boberg KM; Karlsen TH
Hepatology; 2015 Jul; 62(1):188-97. PubMed ID: 25833813
[TBL] [Abstract][Full Text] [Related]
9. Serum aminoterminal propeptide of type III procollagen (S-PIIINP) and hepatobiliary dysfunction in patients with ulcerative colitis.
Leidenius MH; Risteli LT; Risteli JP; Taskinen EI; Kellokumpu IH; Höckerstedt KA
Scand J Clin Lab Invest; 1997 Jul; 57(4):297-305. PubMed ID: 9249877
[TBL] [Abstract][Full Text] [Related]
10. Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis.
Dhillon AK; Kummen M; Trøseid M; Åkra S; Liaskou E; Moum B; Vesterhus M; Karlsen TH; Seljeflot I; Hov JR
Liver Int; 2019 Feb; 39(2):371-381. PubMed ID: 30269440
[TBL] [Abstract][Full Text] [Related]
11. Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis.
Bossen L; Vesterhus M; Hov JR; Färkkilä M; Rosenberg WM; Møller HJ; Boberg KM; Karlsen TH; Grønbæk H
Clin Transl Gastroenterol; 2021 Mar; 12(3):e00315. PubMed ID: 33646203
[TBL] [Abstract][Full Text] [Related]
12. The Natural History of Primary Sclerosing Cholangitis in Children: A Large Single-Center Longitudinal Cohort Study.
Valentino PL; Wiggins S; Harney S; Raza R; Lee CK; Jonas MM
J Pediatr Gastroenterol Nutr; 2016 Dec; 63(6):603-609. PubMed ID: 27504812
[TBL] [Abstract][Full Text] [Related]
13. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
14. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis.
Corpechot C; Gaouar F; El Naggar A; Kemgang A; Wendum D; Poupon R; Carrat F; Chazouillères O
Gastroenterology; 2014 Apr; 146(4):970-9; quiz e15-6. PubMed ID: 24389304
[TBL] [Abstract][Full Text] [Related]
15. Association between serum IgG level and clinical course in primary sclerosing cholangitis.
Hippchen T; Sauer P; Göppert B; Schirmacher P; Gotthardt DN; Weiss KH; Stremmel W; Rupp C
BMC Gastroenterol; 2019 Aug; 19(1):153. PubMed ID: 31455255
[TBL] [Abstract][Full Text] [Related]
16. Appearance of hepatobiliary diseases in a population-based cohort with inflammatory bowel diseases (Inflammatory Bowel Disease Cohort of the Uppsala Region).
Rönnblom A; Holmström T; Tanghöj H; Rorsman F; Sjöberg D
J Gastroenterol Hepatol; 2015 Aug; 30(8):1288-92. PubMed ID: 25777994
[TBL] [Abstract][Full Text] [Related]
17. Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohn's Disease from Ulcerative Colitis.
Mortensen JH; Godskesen LE; Jensen MD; Van Haaften WT; Klinge LG; Olinga P; Dijkstra G; Kjeldsen J; Karsdal MA; Bay-Jensen AC; Krag A
J Crohns Colitis; 2015 Oct; 9(10):863-72. PubMed ID: 26188349
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory Biomarkers of Extracellular Matrix Remodeling and Disease Activity in Crohn's Disease and Ulcerative Colitis.
Domislovic V; Høg Mortensen J; Lindholm M; Kaarsdal MA; Brinar M; Barisic A; Manon-Jensen T; Krznaric Z
J Clin Med; 2022 Oct; 11(19):. PubMed ID: 36233775
[TBL] [Abstract][Full Text] [Related]
19. No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan.
Tanaka A; Tazuma S; Nakazawa T; Isayama H; Tsuyuguchi T; Inui K; Takikawa H
J Hepatobiliary Pancreat Sci; 2017 Apr; 24(4):217-225. PubMed ID: 28103424
[TBL] [Abstract][Full Text] [Related]
20. Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis.
Hilscher M; Enders FB; Carey EJ; Lindor KD; Tabibian JH
Ann Hepatol; 2016; 15(2):246-53. PubMed ID: 26845602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
